SECuRE trial update: First patient treated in the Phase II Cohort Expansion
Sydney, Australia 15 April 2025 Highlights The first of the planned 24 participants in the Cohort Expansion Phase (Phase II) of the SECuRE trial has been treated with their first dose of 8 GBq of 67Cu-SAR-bisPSMA.This follows the recent recommendation by the Safety Review Committee (SRC) after the successful completion of the Dose Escalation Phase…